Dermatology Update 2016
SESSIONS & ABSTRACTS
Montréal, Le Centre Sheraton - NOVEMBER 3-6, 2016
Exploring the role of targeted systemic therapies in the treatment of plaque, nail, scalp, and palmoplantar psoriasis
Objectives and Description:
- Review clinical challenges of treating mild to moderate psoriasis
- Present the role of Otezla in specific patient profiles
Plaque psoriasis is a chronic skin disease presenting erythematous patches that can crack, bleed, are pruritic and painful.1 When nails, scalp, palms, and soles are affected, treatment can be more difficult leading to a poor quality of life. Nail involvement can be challenging to treat and may be associated with a higher risk of developing psoriatic arthritis.2,3 For scalp psoriasis, topicals and photo therapy have limitations due to the presence of hair. Palmoplantar psoriasis does not seem to respond to treatment as well as plaques in other regions, limiting a patient’s everyday tasks and activities.
In planning treatment for plaque psoriasis, the efficacy of the regimen is to be considered against potential safety risks. The areas of the body affected are also an important factor in deciding the appropriate therapy. The traditional approach for the treatment of moderate-to-severe psoriasis has been the use of conventional systemic therapies such as cyclosporine, methotrexate or acitretin. If treatment is not successful or if the disease affects difficult-to-treat areas, biologics targeted against pro-inflammatory cytokines may be considered.
The advent of a new targeted oral systemic therapy, Otezla™ (30 mg apremilast tablets), has brought forward an additional option for the dermatologist treating psoriasis with systemic therapy.4 Apremilast may be considered appropriate for a patient when:
- Active psoriasis is extensive, pruritic and has not responded to topical therapy, phototherapy or conventional systemic therapy.
- Psoriasis is localized and associated with significant functional impairment and/or high levels of distress.
|11:00 – 11:05||Welcome and Introductions||Dr. Charles Lynde|
|11:05 – 11:15||The role of Otezla in plaque psoriasis||Dr. Melinda Gooderham|
|11:15 – 11:20||Q & A|
|11:20 – 11:30||The role of Otezla in Palmar Plantar psoriasis||Dr. Robert Bissonnette|
|11:30 – 11:35||Q & A|
|11:35 – 11:50||The role of Otezla in nail and scalp psoriasis||Dr. Ron Vender|
|11:50 – 11:55||Q & A|
|11:55 – 12:10||Frequently Asked Questions||Dr. Charles Lynde|
|12:10 – 12:15||Conclusion and closing remarks|